<DOC>
	<DOCNO>NCT00850265</DOCNO>
	<brief_summary>Combined inhaled treatment long act adrenergic steroid unique inhaler play important role management non-mild asthma . Some study demonstrate use spacers achieve good lung deposition decrease number side effect . Recently new combine treatment asthma develop ( extrafine formoterol plus beclomethasone dipropionate ) . The small size extrafine particles new combination get small airway theorically improve positive effect . Some author state use spacer extrafine particle could decrease effectiveness treatment due adhesion particle wall spacer electrostatic characteristic plastic spacers . However , clinical functional study demonstrate role phenomenon control asthmatic patient . The investigator ' hypothesis benefit use spacers new treatment least equal magnitude loss efficacy adhesion particles wall spacer investigator hypothesize use spacer extrafine formoterol-beclomethasone suppose decrease clinical functional control stable moderate-severe asthma patient .</brief_summary>
	<brief_title>Effect Spacer Extrafine Formoterol-Beclomethasone Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Moderatesevere asthma Stable asthma 1875 year old Exacerbation asthma Instability study treatment Other cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Extrafine formulation</keyword>
	<keyword>Spacer</keyword>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Stable</keyword>
</DOC>